$89.99
CJC-1295 + Ipamorelin is a synergistic research peptide blend that combines a Growth Hormone Releasing Hormone (GHRH) analog with a selective Growth Hormone Secretagogue. Together, they stimulate the pituitary gland to release endogenous growth hormone in a more natural, pulsatile pattern. This combination is widely studied in preclinical models for its potential to support lean muscle growth, fat metabolism, enhanced recovery, improved sleep quality, and overall anabolic processes while minimizing unwanted effects on cortisol and prolactin levels.
FOR RESEARCH USE ONLY • NOT FOR HUMAN CONSUMPTION Not evaluated by the FDA • Supplied strictly for laboratory and scientific research purposes only.
The CJC-1295 and Ipamorelin blend is a dual-pathway growth hormone secretagogue research combination commonly studied for pituitary signaling, pulsatile growth hormone release, IGF-1 support, recovery models, metabolic pathway research, and endocrine-response studies.
The CJC-1295 and Ipamorelin blend combines two growth hormone secretagogue research peptides that are commonly studied through different but complementary pathways. CJC-1295 is commonly discussed as a growth hormone-releasing hormone pathway analog. Ipamorelin is commonly studied as a ghrelin receptor agonist. Together, the blend is often researched for dual-pathway growth hormone signaling, pulsatile release patterns, IGF-1 support, and broader endocrine-response models. CJC-1295 is commonly studied as a growth hormone-releasing hormone pathway analog. In research models, this pathway is associated with pituitary signaling and growth hormone release. Many research discussions distinguish between CJC-1295 with DAC and CJC-1295 without DAC, because the DAC modification changes the duration-of-activity profile. When the focus is pulsatile signaling, researchers often discuss the shorter-acting, no-DAC version separately from the longer-acting DAC-modified version. Ipamorelin is commonly studied as a ghrelin receptor agonist and growth hormone secretagogue. It is frequently discussed for its selectivity profile in research settings, especially compared with older growth hormone secretagogues that may have broader endocrine effects. The research logic is straightforward: CJC-1295 targets the GHRH receptor pathway, while Ipamorelin targets the ghrelin receptor pathway. Combining the two creates a dual-signal research model for studying growth hormone release, IGF-1 support, recovery models, metabolic pathway behavior, and pulsatile endocrine signaling. The CJC-1295 and Ipamorelin blend is commonly discussed in research settings involving endocrine signaling and growth hormone secretagogue pathways. The blend may be studied in models focused on growth hormone release signaling, pituitary response, and pulsatile endocrine patterns. Because growth hormone signaling is closely associated with downstream IGF-1 research, this blend is often discussed in relation to IGF-1 support models. Growth hormone secretagogue research is frequently connected with recovery, tissue remodeling, and repair-associated pathway models. The blend is also commonly discussed in relation to body composition, fat metabolism, and metabolic pathway research models. Because growth hormone release is linked with sleep-associated endocrine rhythms, this blend may appear in research discussions around restorative processes and circadian timing. Ipamorelin is often discussed for its selectivity profile compared with older secretagogues, especially in relation to cortisol and prolactin pathway concerns. This page is written for a CJC-1295 and Ipamorelin blend, but product pages should be clear about whether the CJC component is with DAC or no DAC. CJC-1295 with DAC is typically discussed as longer-acting. CJC-1295 without DAC, often associated with modified GRF 1-29 terminology, is commonly discussed in relation to shorter-acting, more pulsatile growth hormone release research. It is a research peptide blend commonly studied for growth hormone secretagogue pathways. CJC-1295 is associated with GHRH receptor pathway research, while Ipamorelin is associated with ghrelin receptor pathway research. Researchers commonly discuss the combination because the two peptides represent different upstream signals that may converge on growth hormone release pathways. No. This blend is intended strictly for laboratory research use only. It is not for human consumption, not for animal use, and not intended for medical, therapeutic, diagnostic, or veterinary applications. This page describes research pathways only. The blend is commonly studied in growth hormone secretagogue models, but it should not be marketed as producing a human health outcome. Ipamorelin is often discussed in research settings for its selectivity profile compared with older growth hormone secretagogues. Avoid making medical or human-use claims. Not exactly. CJC-1295 with DAC and CJC-1295 without DAC are discussed differently because the DAC modification changes the duration-of-activity profile. Product pages should clearly state which version is being referenced.What Is the CJC-1295 & Ipamorelin Blend?
CJC-1295GHRH receptor pathway research, pituitary signaling, and growth hormone release models.
IpamorelinGhrelin receptor pathway research, selective GH secretagogue activity, and endocrine-response models.
Blend SynergyDual-pathway research model combining GHRH receptor signaling with ghrelin receptor activation.
Research FocusGrowth hormone release, IGF-1 support, recovery models, metabolic research, and pulsatile signaling studies.
How the Blend Works in Research Models
CJC-1295 — GHRH Pathway Research
Ipamorelin — Ghrelin Receptor Pathway Research
Why Researchers Combine Them
Combined Blend Takeaway: CJC-1295 and Ipamorelin are commonly paired in research because they represent two different upstream signals that may converge on growth hormone release pathways.
Mechanism Comparison Chart
Research Pathway / Effect
CJC-1295
Ipamorelin
Blend
Growth hormone release research
Strong
Strong
Strong synergy
IGF-1 support models
Strong
Moderate to strong
Strong synergy
Pituitary signaling research
Strong
Moderate
Dual-pathway model
Ghrelin receptor research
Indirect
Strong
Complementary
Pulsatile release research
Strong with no-DAC format
Strong
Strong
Recovery and tissue research models
Supportive
Supportive
Complementary
Metabolic pathway research
Supportive
Supportive
Complementary
Cortisol / prolactin selectivity discussion
Not the main pathway
Common research angle
Ipamorelin-driven selectivity angle
Duration of activity
Depends on DAC vs no-DAC
Short to moderate
Depends on formula design
Research Applications
Growth Hormone Signaling Research
IGF-1 Support Models
Recovery Pathway Research
Metabolic Research
Sleep and Circadian Research
Endocrine Selectivity Research
CJC-1295 With DAC vs No DAC
Frequently Asked Questions
What is the CJC-1295 and Ipamorelin blend?
Why combine CJC-1295 with Ipamorelin?
Is this blend for human use?
Does this blend increase growth hormone?
Does Ipamorelin affect cortisol or prolactin?
Is CJC-1295 the same as CJC-1295 no DAC?
Learn about the CJC-1295 and Ipamorelin blend, a research peptide combination studied for growth hormone secretagogue pathways, pituitary signaling, pulsatile GH release, IGF-1 support, recovery models, and metabolic research. For laboratory research use only.
| size | 5/5 MG, 10/10 MG |
|---|
Only logged in customers who have purchased this product may leave a review.
This website offers products intended strictly for laboratory and scientific research purposes only.
These products are not for human or animal consumption and are not medical products.
By entering, you confirm that you are 18 years or older and accessing this site for legitimate research purposes only.
Reviews
There are no reviews yet.